Major neurodevelopmental disability at childhood · Neonates, including term neonates (gestational age ≥ 37 weeks), late preterm neonates (35 to 37 weeks' gestation) and preterm neonates (<…
1 finding from 1 review
Major neurodevelopmental disability at childhood · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability ‒not reported · very preterm infants with or at risk of germinal matrix‐intraventricular haemorrhage in preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants prior to extubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk for apnea
Methylxanthine showed no clear difference in death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants with apnea
Methylxanthine showed no clear difference in death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants prior to extubation
Methylxanthine probably leads to lower death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants at risk for apnea
It is very uncertain whether high‐dose changes major neurodevelopmental disability in children aged 3 to 5 years CA compared with standard‐dose strategies (very low certainty).
1 finding from 1 review
Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Major neurodevelopmental disability in infancy · late preterm or term newborns with hypoxic‐ischaemic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability at childhood · infants with perinatal asphyxia
It is very uncertain whether barbiturate treatment changes major neurodevelopmental disability compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Major neurodevelopmental disability at school age · late preterm or term newborns with hypoxic‐ischaemic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Death or major neurodevelopmental disability in infancy · late preterm or term newborns with hypoxic‐ischaemic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found